U.S. markets closed
  • S&P Futures

    4,172.50
    -11.00 (-0.26%)
     
  • Dow Futures

    34,633.00
    -35.00 (-0.10%)
     
  • Nasdaq Futures

    13,296.25
    -60.50 (-0.45%)
     
  • Russell 2000 Futures

    2,196.20
    -13.40 (-0.61%)
     
  • Crude Oil

    64.68
    -0.24 (-0.37%)
     
  • Gold

    1,835.10
    -2.50 (-0.14%)
     
  • Silver

    27.35
    -0.14 (-0.50%)
     
  • EUR/USD

    1.2134
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.6020
    +0.0250 (+1.59%)
     
  • Vix

    19.66
    +2.97 (+17.80%)
     
  • GBP/USD

    1.4118
    -0.0004 (-0.03%)
     
  • USD/JPY

    108.9500
    +0.1090 (+0.10%)
     
  • BTC-USD

    55,625.46
    -3,104.30 (-5.29%)
     
  • CMC Crypto 200

    1,462.74
    -98.56 (-6.31%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    29,013.06
    -505.28 (-1.71%)
     

Anavex Soars on Positive Alzheimer’s Results

Chris Lange

Anavex Life Sciences Corp. (AVXL) was one of the stocks helping to prop up the market in Monday’s session. The company reported a positive dose-response relationship has been observed in a pre-planned interim analysis of data from the ongoing Phase 2a trial of Anavex 2-73 for treatment of mild to moderate Alzheimer’s disease.

Among 32 patients treated with doses of Anavex 2-73 ranging from 3 mg to 50 mg a day, the Mini Mental State Examination (MMSE) score data showed a positive slope with confidence intervals not including the zero-value, consistent with a dose dependent improvement in MMSE scores over five weeks.

ALSO READ: 12 Things Not to Do If You Win the $1.3 Billion Lottery

Norman Relkin, MD, PhD, an Alzheimer clinical trialist and an advisor to Anavex, commented:

While we remain cautious about interpreting the results of an interim analysis, evidence of ANAVEX 2-73’s positive dose response at 5 weeks on the MMSE is a welcome signal. Evidence of a dose-response relationship is one of the factors taken into account by regulatory agencies when ultimately considering medications for approval.

Christopher U. Missling, PhD, president and CEO of Anavex, added:

Our team is encouraged by these findings and we look forward to advancing ANAVEX 2-73 into a larger Phase 2/3 study for Alzheimer’s as well as initiating a double-blinded, randomized, placebo-controlled Phase 2 trial for ANAVEX 2-73 in an additional indication associated with cognitive impairment.

ALSO READ: Best and Worst Car Brands in America


Previously the company announced positive data for its Anavex 3-71, which is also involved in the treatment of Alzheimer’s. Despite the positive data that this company has been releasing surrounding its Alzheimer’s study, the stock has dropped nearly 30% in the past month and 17% year to date.

Shares of Anavex were last seen trading up 10.4% at $5.08, with a consensus analyst price target of $10.16 and a 52-week trading range of $3.16 to $14.84.

Related Articles